Walker Methodist Westwood Ridge: Bleeding Risk Ignored - MN
Walker Methodist Westwood Ridge II admitted the resident on April 6 and immediately began administering Eliquis, a potent anticoagulant prescribed twice daily to treat atrial fibrillation. The medication carries well-documented bleeding risks, including blood in gums, nose, urine, and stools.
Yet the facility's electronic medical records contained no evidence anyone was watching for these potentially dangerous side effects.
The resident's medication administration record showed no monitoring protocols. The active orders contained no bleeding assessments. The care plan made no mention of anticoagulation surveillance.
"Medication side effect monitoring should show up on each residents' medication and treatment administration record to be documented on every shift," registered nurse RN-B told inspectors on April 14.
The clinical coordinator confirmed the obvious gap. Licensed practical nurse LPN-A acknowledged during her April 14 interview that the resident "did not have any medication side effect monitoring in place and that it would be expected."
This wasn't an administrative oversight. The resident carried a diagnosis of unspecified atrial fibrillation from January 2025 — a condition that makes blood-thinning medication both necessary and risky. Eliquis prevents strokes by reducing blood clotting, but that same mechanism can trigger internal bleeding that proves difficult to detect and stop.
The director of nursing offered a defense that highlighted the facility's inconsistent approach to medication safety. During her April 15 interview, she claimed "side effect monitoring is focused more closely on high-risk medications" and said such monitoring gets "incorporated into the care plan, with specific elements added to the kardex for aides to observe."
She specifically mentioned that "anticoagulants are monitored for signs of bleeding or bruising."
But the resident's records contradicted her explanation entirely.
The inspection revealed a facility operating without clear medication monitoring protocols. When inspectors requested the facility's policy on side effect monitoring, staff never provided it.
This gap in care occurred during the resident's first week at the facility — precisely when new medication regimens require the closest attention. The resident had been at Walker Methodist Westwood Ridge II for just nine days when inspectors discovered the monitoring failure.
The stakes of anticoagulation monitoring extend beyond paperwork compliance. Bleeding complications from blood thinners can progress rapidly from minor symptoms to life-threatening hemorrhages. Early detection requires systematic observation of the subtle signs nursing staff encounter during routine care — unusual bruising during bathing, blood traces during oral care, changes in urine color, or alterations in bowel movements.
Without documented monitoring protocols, these critical observations become random rather than systematic. Staff members might notice bleeding symptoms, but they might not. The resident's safety depends on chance rather than clinical procedure.
The facility's approach created a dangerous contradiction: prescribing a high-risk medication while failing to implement the monitoring systems that make its use safe. The director of nursing knew anticoagulants required bleeding surveillance. The registered nurse understood that monitoring should appear on every shift's documentation. The clinical coordinator recognized the expectation for such protocols.
Yet none of these staff members ensured the resident actually received the monitoring they all acknowledged was necessary.
Federal inspectors classified this as a violation with minimal harm or potential for actual harm. But the resident remained on Eliquis throughout the inspection period, accumulating days of unmonitored exposure to bleeding risks.
The resident's medical record now documents not just atrial fibrillation and anticoagulation therapy, but also a facility's failure to bridge the gap between prescribing a dangerous medication and ensuring its safe administration.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Walker Methodist Westwood Ridge II from 2026-04-15 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
WALKER METHODIST WESTWOOD RIDGE II in WEST SAINT PAUL, MN was cited for violations during a health inspection on April 15, 2026.
The medication carries well-documented bleeding risks, including blood in gums, nose, urine, and stools.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.